EXPERIENCE OF TREATMENT with ANTI-PD-1: FROM WORLD STANDARDS TO REAL CLINICAL PRACTICE (CLINICAL OBSERVATION)
- Authors: Zhukova N.V1, Orlova R.V1,2, Antimonik N.Y.1, Kutukova S.I1,3, Belyak N.P1, Popova N.V1
-
Affiliations:
- City Clinical Oncological Dispensary
- St. Petersburg State University
- Acad. I.P. Pavlov First St. Petersburg State Medical University
- Issue: No 7 (2018)
- Pages: 40-44
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/295458
- ID: 295458
Cite item
Abstract
Full Text
About the authors
N. V Zhukova
City Clinical Oncological Dispensary
Email: natalia-zhukova@yandex.ru
St. Petersburg
R. V Orlova
City Clinical Oncological Dispensary; St. Petersburg State UniversitySt. Petersburg
N. Yu Antimonik
City Clinical Oncological DispensarySt. Petersburg
S. I Kutukova
City Clinical Oncological Dispensary; Acad. I.P. Pavlov First St. Petersburg State Medical UniversitySt. Petersburg
N. P Belyak
City Clinical Oncological DispensarySt. Petersburg
N. V Popova
City Clinical Oncological DispensarySt. Petersburg
References
- Hodi F.S, Kluger H., Sznol M., et al. Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial. Oral presentation at: AACR Annual Meeting 2016, abstr. CT001.
- Larkin J., Minor D., DAngelo S., et al. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open- Label Phase III Trial. J. Clin. Oncol. 2018;36(4):383-90.
- Robert C., Long G.V., Brady B., et al. Nivolumab in previously untreated melanoma whithout BRAF mutation. N. Engl. J. Med. 2015;372(4): 320-30.
- Schadendorf D., Hodi F.S., Robert C., et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol. 2015;33(17):1889-94.
- Weber J.S., Hodi F.S., Wolchjok J.D., et al. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. J Clin Oncol. 2017;35(7)785-91.
- Weber J.S., DAngelo S.Р., Minor D., et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(6):37-84.